<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328938</url>
  </required_header>
  <id_info>
    <org_study_id>GCPGC P2/3</org_study_id>
    <nct_id>NCT01328938</nct_id>
  </id_info>
  <brief_title>GCPGC in Chemotherapy-induced Neutropenia</brief_title>
  <official_title>A Randomized,Multi-center,Parallel-group, Phase II(Single-blind)/Phase III(Double- Blind)Study to Determine the Optimal Dose and to Evaluate the Efficacy and Safety of GCPGC on Chemotherapy-induced Neutropenia Compared to Neulasta(Pegfilgrastim)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symyoo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is adaptive design and it consists of stage I and stage II.

      Stage I is multi-center, parallel-group, single-blind, phase II study to determine the
      adequate dose of GCPGC in chemotherapy-induced neutropenia. 2 Different doses of GCPGC will
      be investigated in a total of 60 Breast cancer patients who are receiving chemotherapy.

      Stage II is multi-center, parallel-group, double-blind,phase III study to evaluate the
      efficacy and safety of once per cycle GCPGC in chemotherapy-induced neutropenia compared to
      Neulasta (pegfilgrastim). A total of 120 patients receiving chemotherapy will participate
      into this phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GCPGC ia a solution for containing pegfilgrastim. Pegfilgrastim is a covalent conjugate of
      recombinant human granulocyte colony-stimulating factor (G-CSF) with a polyethylene glycol
      (PEG) which has long half life compared to filgrastim, resulting in dosing advantage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of grade 4 neutropenia(ANC&lt;500mm3) for cycle 1</measure>
    <time_frame>in cycle 1</time_frame>
    <description>Stage I: The difference in mean duration of grade 4 neutropenia between GCPGC 3.6mg and GCPGC 6mg is measured by check ANC in cycle I.
Stage II : The difference in mean duration of grade 4 neutropenia between GCPGC which dose was determined at Stage I and Neulasta is measured by check ANC in cycle 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ANC recovery (≥2,000/mm3) after nadir in cycle 1</measure>
    <time_frame>in cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of ANC nadir in cycle 1</measure>
    <time_frame>in cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Febrile neutropenia in all cycles</measure>
    <time_frame>in all cycles</time_frame>
    <description>Stage I: only in cycle 1; Stage II: in all cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of severe neutropenia persisting more than 3 days in cycle 1 (only for Stage II)</measure>
    <time_frame>in cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC values at Day 7 in all cycles (only for Stage II)</measure>
    <time_frame>Day 7 in alll cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of delay or dose-reduction of chemotherapy due to neutropenia (only for Stage II)</measure>
    <time_frame>all cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization due to febrile neutropenia in cycle 2 and after (only for Stage II)</measure>
    <time_frame>in clycle 2-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intravenous antimicrobial treatments due to febrile neutropenia</measure>
    <time_frame>in all cycles</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of antibody development in patients receiving GCPGC compared to Neulasta</measure>
    <time_frame>3 months after last treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital sign, Physical examination, Laboratory tests, Occurrence of adverse reactions</measure>
    <time_frame>in all cycles</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Chemotherapy Induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>Stage I - Arm I: GCPGC I (3.6mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I - Arm II: GCPGC II (6mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II - Arm I: GCPGC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).
The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II - Arm II: Neulasta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GCPGC 3.6mg</intervention_name>
    <description>Stage I:Single blinded</description>
    <arm_group_label>Stage I - Arm I: GCPGC I (3.6mg)</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GCPGC 6mg</intervention_name>
    <description>Stage I: Single blinded;</description>
    <arm_group_label>Stage I - Arm II: GCPGC II (6mg)</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neulasta (pegfilgrastim) 6mg</intervention_name>
    <description>Stage II: Active comparator, double blinded</description>
    <arm_group_label>Stage II - Arm II: Neulasta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GCPGC 6mg</intervention_name>
    <description>Experimental: Stage II</description>
    <arm_group_label>Stage II - Arm I: GCPGC</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women(≥ 18 years old) diagnosed with breast cancer who are receiving chemotherapy
             inducing neutropenia

          -  body weight of 45kg and more

          -  ECOG performance status 2 and less

          -  ANC ≥1,500mm3 and Platelet ≥100,000/mm3

          -  life expectancy of 3 months and more

          -  given written informed consent

        Exclusion Criteria:

          -  had previous exposure to pegfilgrastim or filgrastim

          -  had received systemic antibiotics within 72hrs of chemotherapy

          -  prior total cumulative lifetime exposure to doxorubicin more than 240 mg/m or
             epirubicin more than 600 mg/m
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Do-Youn Oh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-Hee Lee, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Green Cross Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seock-Ah Im, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungju</city>
        <state>Chungchungbuk</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Ilsan</city>
        <state>KyungKi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <state>KyungKi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Sungnam</city>
        <state>Kyungki</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

